Posoleucel
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04605484 | Mar 2021 → Oct 2022 | BK-virus nephropathy, polyomavirus infectious disease | AlloVir | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT05305040 | Mar 2022 → Jan 2024 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection, polyomavirus infectious disease +1 | AlloVir | Terminated | Missed primary |
| Phase 2/3 | NCT04693637 | Jan 2021 → Jan 2023 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection, polyomavirus infectious disease | AlloVir | Completed | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT05179057 | Apr 2022 → Jan 2024 | adenoviridae infectious disease | AlloVir | Terminated | Missed primary |
| Phase 3 | NCT04390113 | Mar 2021 → Jan 2024 | hemorrhagic cystitis, polyomavirus infectious disease | AlloVir | Terminated | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT02108522 | Jun 2014 → Dec 2018 | infectious disease | AlloVir | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Posoleucel | “Posoleucel is a multivirus-specific T-cell therapy for off-the-shelf use against six viral infections that commonly occur in allo-HCT recipients: adenovirus, BK virus (BKV),...” PMID 36628536 ↗ Jan 2023 |
| Known as | ALVR105 | “This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens:...” NCT04693637 ↗4“This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK...” NCT05305040 ↗ “Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation” NCT05179057 ↗ “Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia” NCT04605484 ↗ “Posoleucel (ALVR105)” NCT04390113 ↗ |
| Known as | Viralym-M | “This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens:...” NCT04693637 ↗1“Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia” NCT04605484 ↗ |
| Modality | Cell therapy | “Posoleucel is a multivirus-specific T-cell therapy for off-the-shelf use against six viral infections” PMID 36628536 ↗ Jan 2023 |
| Route | Intravenous | “the VSTs will be thawed and injected into their intravenous line” NCT02108522 ↗ |